214 related articles for article (PubMed ID: 20147525)
1. 1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion.
Washington MN; Weigel NL
Endocrinology; 2010 Apr; 151(4):1409-17. PubMed ID: 20147525
[TBL] [Abstract][Full Text] [Related]
2. Vitamin D receptor activation reduces VCaP xenograft tumor growth and counteracts ERG activity despite induction of TMPRSS2:ERG.
Roberts JM; Martin RS; Piyarathna DB; MacKrell JG; Rocha GV; Dodge JA; Coarfa C; Krishnan V; Rowley DR; Weigel NL
Oncotarget; 2017 Jul; 8(27):44447-44464. PubMed ID: 28591703
[TBL] [Abstract][Full Text] [Related]
3. The prostate cancer TMPRSS2:ERG fusion synergizes with the vitamin D receptor (VDR) to induce CYP24A1 expression-limiting VDR signaling.
Kim JS; Roberts JM; Bingman WE; Shao L; Wang J; Ittmann MM; Weigel NL
Endocrinology; 2014 Sep; 155(9):3262-73. PubMed ID: 24926821
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
5. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer.
Björkman M; Iljin K; Halonen P; Sara H; Kaivanto E; Nees M; Kallioniemi OP
Int J Cancer; 2008 Dec; 123(12):2774-81. PubMed ID: 18798265
[TBL] [Abstract][Full Text] [Related]
6. Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells.
Mohamed AA; Tan SH; Xavier CP; Katta S; Huang W; Ravindranath L; Jamal M; Li H; Srivastava M; Srivatsan ES; Sreenath TL; McLeod DG; Srinivasan A; Petrovics G; Dobi A; Srivastava S
Mol Cancer Res; 2017 Oct; 15(10):1308-1317. PubMed ID: 28607007
[TBL] [Abstract][Full Text] [Related]
7. TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model.
Semaan L; Mander N; Cher ML; Chinni SR
BMC Cancer; 2019 Oct; 19(1):972. PubMed ID: 31638934
[TBL] [Abstract][Full Text] [Related]
8. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.
Pflueger D; Rickman DS; Sboner A; Perner S; LaFargue CJ; Svensson MA; Moss BJ; Kitabayashi N; Pan Y; de la Taille A; Kuefer R; Tewari AK; Demichelis F; Chee MS; Gerstein MB; Rubin MA
Neoplasia; 2009 Aug; 11(8):804-11. PubMed ID: 19649210
[TBL] [Abstract][Full Text] [Related]
9. 1alpha,25-Dihydroxyvitamin D3 down-regulates expression of prostate specific membrane antigen in prostate cancer cells.
Serda RE; Bisoffi M; Thompson TA; Ji M; Omdahl JL; Sillerud LO
Prostate; 2008 May; 68(7):773-83. PubMed ID: 18247401
[TBL] [Abstract][Full Text] [Related]
10. Role of the TMPRSS2-ERG gene fusion in prostate cancer.
Tomlins SA; Laxman B; Varambally S; Cao X; Yu J; Helgeson BE; Cao Q; Prensner JR; Rubin MA; Shah RB; Mehra R; Chinnaiyan AM
Neoplasia; 2008 Feb; 10(2):177-88. PubMed ID: 18283340
[TBL] [Abstract][Full Text] [Related]
11. Role of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression.
Yin L; Rao P; Elson P; Wang J; Ittmann M; Heston WD
PLoS One; 2011; 6(6):e21319. PubMed ID: 21731703
[TBL] [Abstract][Full Text] [Related]
12. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
[TBL] [Abstract][Full Text] [Related]
13. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer.
Cai C; Wang H; He HH; Chen S; He L; Ma F; Mucci L; Wang Q; Fiore C; Sowalsky AG; Loda M; Liu XS; Brown M; Balk SP; Yuan X
J Clin Invest; 2013 Mar; 123(3):1109-22. PubMed ID: 23426182
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of fatty acid synthase expression by 1alpha,25-dihydroxyvitamin D3 in prostate cancer cells.
Qiao S; Pennanen P; Nazarova N; Lou YR; Tuohimaa P
J Steroid Biochem Mol Biol; 2003 May; 85(1):1-8. PubMed ID: 12798352
[TBL] [Abstract][Full Text] [Related]
15. TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation.
Mounir Z; Lin F; Lin VG; Korn JM; Yu Y; Valdez R; Aina OH; Buchwalter G; Jaffe AB; Korpal M; Zhu P; Brown M; Cardiff RD; Rocnik JL; Yang Y; Pagliarini R
Oncogene; 2015 Jul; 34(29):3815-25. PubMed ID: 25263440
[TBL] [Abstract][Full Text] [Related]
16. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.
Setlur SR; Mertz KD; Hoshida Y; Demichelis F; Lupien M; Perner S; Sboner A; Pawitan Y; Andrén O; Johnson LA; Tang J; Adami HO; Calza S; Chinnaiyan AM; Rhodes D; Tomlins S; Fall K; Mucci LA; Kantoff PW; Stampfer MJ; Andersson SO; Varenhorst E; Johansson JE; Brown M; Golub TR; Rubin MA
J Natl Cancer Inst; 2008 Jun; 100(11):815-25. PubMed ID: 18505969
[TBL] [Abstract][Full Text] [Related]
17. Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer.
Todorova K; Metodiev MV; Metodieva G; Mincheff M; Fernández N; Hayrabedyan S
Horm Cancer; 2017 Feb; 8(1):28-48. PubMed ID: 28050800
[TBL] [Abstract][Full Text] [Related]
18. Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.
Ateeq B; Vellaichamy A; Tomlins SA; Wang R; Cao Q; Lonigro RJ; Pienta KJ; Varambally S
Prostate; 2012 Oct; 72(14):1542-9. PubMed ID: 22415461
[TBL] [Abstract][Full Text] [Related]
19. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.
Zhao XY; Ly LH; Peehl DM; Feldman D
Endocrinology; 1997 Aug; 138(8):3290-8. PubMed ID: 9231780
[TBL] [Abstract][Full Text] [Related]
20. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.
Zhao XY; Peehl DM; Navone NM; Feldman D
Endocrinology; 2000 Jul; 141(7):2548-56. PubMed ID: 10875257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]